NCT05503550 2025-12-16
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
No longer available
Clinical Trials
12 trialsNCT05918913 2025-09-05
Expanded Access Program for Revumenib
Syndax Pharmaceuticals
No longer available
NCT05238311 2025-02-04
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Pfizer
No longer available
NCT04052854 2024-10-23
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
BeiGene
No longer available
NCT05462639 2024-08-09
MAGNETISMM17
Pfizer
No longer available
NCT05131438 2023-03-27
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
EQRx International, Inc.
No longer available
NCT04678466 2022-05-31
Flotetuzumab Expanded Access Program
MacroGenics
No longer available
NCT04705454 2021-05-12
Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.
No longer available
NCT02568943 2020-04-08
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
Novartis
No longer available
NCT02715843 2019-10-11
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Molecular Templates, Inc.
No longer available
NCT01432483 2015-01-26
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Eisai Inc.
No longer available
NCT00063791 2007-02-14
A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
Millennium Pharmaceuticals, Inc.
No longer available